Market Place
Sourcing Support
GC Pharma Receives Complete Response Letter From the U.S. FDA For `ALYGLO`
26 Feb 2022 //
BUSINESSWIRE
GC Pharma Reports Full Year 2021 Results
14 Feb 2022 //
BUSINESSWIRE
EMA Grants ODD to GC Pharma`s Hunterase ICV, for Mucopolysaccharidosis Type II
01 Nov 2021 //
BUSINESSWIRE
GC Pharma in talks with J&J for COVID-19 vaccine deal
28 Sep 2021 //
KOREAHERALD
FDA Action Alert: Mirum and Kite/Gilead
27 Sep 2021 //
BIOSPACE
S. Korea‘s mRNA vaccine consortium gets two new members
09 Sep 2021 //
KOREAHERALD
GC Pharma Announces GreenGene F Approval in China for Treating Haemophilia A
12 Aug 2021 //
BUSINESSWIRE
GC Pharma and Tottori Univ. Ink Pact for GM1 Gangliosidosis Chaperone Therapy
02 Aug 2021 //
BUSINESS WIRE
GC Pharma Reports Q2 2021 Results
02 Aug 2021 //
BUSINESS WIRE
US FDA Accepts GC Pharma’s Biologics License Application `GC5107`
06 May 2021 //
BUSINESSWIRE
GC Pharma Finalises Agreement With Moderna & the Govt of the Republic of Korea
03 Mar 2021 //
BUSINESSWIRE
GC Pharma Submits BLA to US FDA for Immune Globulin `GC5107`
26 Feb 2021 //
BUSINESSWIRE
GC Pharma Submits Biologics License Application to US FDA for Globulin `GC5107`
25 Feb 2021 //
BUSINESSWIRE
GC Pharma Submits Biologics License Application to US FDA `GC5107`
25 Feb 2021 //
BUSINESSWIRE
GC Pharma completes phase 2 trial of COVID-19 plasma therapy treatment
06 Jan 2021 //
KOREAHERALD
Kanaph therapeutics closes 21M USD Series B funding
12 Oct 2020 //
BIOSPECTRUMASIA
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.